基本信息
浏览量:100
职业迁徙
个人简介
Dr. Tengfei Ted Xiao is a Co-Founder and the Chief Technology Officer of GV20 Oncotherapy. Ted founded GV20 Oncotherapy in 2016, after he finished his postdoctoral research training in Myles Brown lab at Dana-Farber Cancer Institute (DFCI). He was a pioneer of building up a functional CRISPR screening platform at DFCI. His expertise includes cancergenomics, high throughput screening techniques and bioinformatics. In GV20, he leads teams to build an AI-based antibody screening platform and has discovered several novel targets for cancer immunotherapy.
研究兴趣
论文共 49 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
X. Shirley Liu, Yulong Li, Xiangyang Wu,Hailing Liu, Huizhu Liu, Caibin Sheng, Qingyang Ding, Yixuan Tang, Chao Liu, Bin Xie, Xi Xiao, Quan Yu,
Cancer Researchno. 6_Supplement (2024): 3914-3914
Bin Xie, Yulong Li,Karim A Benhadji,X Shirley Liu, Xiangyang Wu, Hailing Liu, Xi Xiao, Huizhu Liu, Qingyang Ding, Caibin Sheng,Rongbin Zheng, Quan Yu,
Journal for ImmunoTherapy of Cancerno. Suppl 1 (2023)
引用0浏览0引用
0
0
Annals of Oncology (2023): S187-S188
引用0浏览0引用
0
0
Cancer Researchno. 4 (2022): P4-01
Proceedings of the National Academy of Sciencesno. 3 (2022): e2105898119-e2105898119
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Poster Presentations - Proffered Abstracts (2021)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn